Fundamental Analysis of NOVAVAX INC(NASDAQ:NVAX) stock

Fundamental Rating

Overall NVAX gets a fundamental rating of 2 out of 10. We evaluated NVAX against 565 industry peers in the Biotechnology industry. NVAX has a bad profitability rating. Also its financial health evaluation is rather negative. NVAX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NVAX has reported negative net income.

NVAX had a negative operating cash flow in the past year.

In the past 5 years NVAX always reported negative net income.

NVAX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -16.63%, NVAX belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-16.63%
ROE	N/A
ROIC	N/A

ROA(3y)-42.37%

ROA(5y)-46.05%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 63.79%, NVAX belongs to the top of the industry, outperforming 81.11% of the companies in the same industry.

NVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.79%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.

NVAX has more shares outstanding than it did 1 year ago.

NVAX has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, NVAX has an improved debt to assets ratio.

2.2 Solvency

NVAX has an Altman-Z score of -3.78. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.

NVAX has a Altman-Z score of -3.78. This is comparable to the rest of the industry: NVAX outperforms 44.92% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-3.78

ROIC/WACCN/A

WACC9.91%

2.3 Liquidity

A Current Ratio of 0.93 indicates that NVAX may have some problems paying its short term obligations.

Looking at the Current ratio, with a value of 0.93, NVAX is doing worse than 88.77% of the companies in the same industry.

A Quick Ratio of 0.93 indicates that NVAX may have some problems paying its short term obligations.

The Quick ratio of NVAX (0.93) is worse than 87.52% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.93
Quick Ratio	0.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.52%, which is quite impressive.

The Revenue for NVAX has decreased by -15.68% in the past year. This is quite bad

The Revenue has been growing by 95.67% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)64.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.68%

Revenue 1Y (TTM)-15.68%

Revenue growth 3Y27.41%

Revenue growth 5Y95.67%

Sales Q2Q%-54.8%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.04% on average per year.

The Revenue is expected to decrease by -3.33% on average over the next years.

EPS Next Y85.11%

EPS Next 2Y40.35%

EPS Next 3Y29.34%

EPS Next 5Y16.04%

Revenue Next Year-24.96%

Revenue Next 2Y-26.65%

Revenue Next 3Y-13.97%

Revenue Next 5Y-3.33%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NVAX's earnings are expected to grow with 29.34% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.35%

EPS Next 3Y29.34%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NVAX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVAVAX INC

NASDAQ:NVAX (11/21/2024, 8:00:02 PM)

Premarket: 7.99 -0.05 (-0.62%)

8.04

-0.02 (-0.25%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.29B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.63%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	63.79%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.52

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.93
Quick Ratio	0.93
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)64.52%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y85.11%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-15.68%

Revenue growth 3Y27.41%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NOVAVAX INC (NVAX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens